GlassScriptPhysician profile
Lini M Thomas
NPI 1093338832
$2,932.12
in general payments reported to CMS, 2019-2025
24 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $230 · 2024: $1,266 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $469.51 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $383.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $344.42 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $275.84 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $264.48 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.83 | 2024-2025 | Jardiance |
| Pfizer INC. | $216.72 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.45 | 2023-2025 | Trintellix |
| Astellas Pharma US INC | $91.37 | 2024-2025 | Veozah |
| Cipher Pharmaceuticals US LLC | $75.76 | 2025 | Natroba, Spinosad |
| Otsuka America Pharmaceutical, INC. | $58.65 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.10 | 2024-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $43.08 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $42.07 | 2024-2025 | Sunosi, Auvelity |
| Dexcom, INC. | $39.79 | 2023-2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.99 | 2025 | |
| Hikma Pharmaceuticals USA | $29.27 | 2024 | Ryaltris |
| Xeris Pharmaceuticals, INC. | $18.31 | 2025 | Keveyis |
| Amgen INC. | $17.84 | 2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $15.87 | 2024 | |
| Exact Sciences Corporation | $15.71 | 2023 | Cologuard Collection Kit |
| Optinose US, INC. | $14.99 | 2024 | |
| Sumitomo Pharma America, INC. | $14.17 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lini Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.